What's Happening?
Corcept Therapeutics has presented final data from its Phase 3 ROSELLA trial, demonstrating that the combination of Lifyorli (relacorilant) and nab-paclitaxel significantly improves overall survival in patients with platinum-resistant ovarian cancer.
The trial results, presented at the Society of Gynecologic Oncology's Annual Meeting and published in The Lancet, show a 35% reduction in the risk of death for patients receiving the combination therapy compared to nab-paclitaxel alone. The FDA approved Lifyorli in March 2026, marking it as the first selective glucocorticoid receptor antagonist for this patient group. The treatment has been added to the National Comprehensive Cancer Network's guidelines as a preferred regimen.
Why It's Important?
The approval and successful trial results of Lifyorli represent a significant advancement in the treatment of platinum-resistant ovarian cancer, a condition with limited therapeutic options. The improved survival rates offer hope to patients and oncologists, potentially establishing Lifyorli as a new standard of care in the U.S. The findings underscore the importance of cortisol modulation in oncology, as cortisol can inhibit chemotherapy effectiveness and promote tumor growth. This development may lead to broader applications of glucocorticoid receptor antagonists in other cancer types, enhancing treatment options and outcomes for patients.
What's Next?
Corcept Therapeutics plans to continue its research into cortisol modulation across various solid tumors expressing the glucocorticoid receptor. The company is also seeking regulatory approval for relacorilant in Europe, which could expand its market and provide more patients access to this promising treatment. Ongoing trials and collaborations with international oncology groups will further explore the potential of relacorilant in treating other cancers, including endometrial, cervical, pancreatic, and prostate cancers.
